Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Liwei Lv, Liu Zixian, Yan-ying Wang, Jie Li, He-Bing Zhou, Li Hong Li, Zhenling Li, Liang Wang

Blood (2025) 146 (Supplement 1): 7227.

https://doi.org/10.1182/blood-2025-7227

Published: 2025

Journal Articles

Who participates in myeloma trials? clinical and geographic predictors of access and outcomes in British Columbia, Canada.

Blood (2025) 146 (Supplement 1): 2815.

https://doi.org/10.1182/blood-2025-2815

Published: 2025

Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song

Blood (2025) 146 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2025-5368

Published: 2025

Journal Articles

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Andrew D. Trunk, Hong Li, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2024-204051

Published: 2024

Journal Articles

Effect of Prior Daratumumab Treatment on Hematopoietic Progenitor Cell Mobilization in Newly Diagnosed Multiple Myeloma

Daniel Cancilla, Joseph Farinella, Amanda Inman, Hong Li, Craig S. Sauter, Faiz Anwer, Claudio Brunstein, Shahzad Raza, Louis Williams, Jack Khouri

Blood (2024) 144 (Supplement 1): 7260.

https://doi.org/10.1182/blood-2024-209082

Published: 2024

Journal Articles

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Victoria Stepanyants, Hong Li, Danielle Cenin, Jessi Edwards, Claudio Brunstein, Matt Kalaycio, Ronald Sobecks, Craig S. Sauter, Betty K. Hamilton

Blood (2024) 144 (Supplement 1): 2145.

https://doi.org/10.1182/blood-2024-199329

Published: 2024

Journal Articles

Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia

Hassan Elmaleh, Hong Li, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Beth M. Faiman, Jack Khouri, Jason Valent, Faiz Anwer, Louis S Williams

Blood (2024) 144 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2024-208780

Published: 2024

Journal Articles

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Ronald Sobecks, Hong Li, Danielle Cenin, Seema Patel, Jesse Edwards, Stephanie Farlow, Amelia Bragg, Rabi Hanna, Seth J Rotz, Deepa Jagadeesh, Aaron T. Gerds, Robert M. Dean, Brad Pohlman, Betty K. Hamilton, Claudio Brunstein, Matt Kalaycio, Craig S Sauter

Blood (2023) 142 (Supplement 1): 3621.

https://doi.org/10.1182/blood-2023-187071

Published: 2023

Journal Articles

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Brian T. Hill, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Robert M. Dean, Deepa Jagadeesh, Kasra Karamlou, Chieh-Lin Fu, Allison Winter, Ethan Krauspe, Jonathan Zhou, Taylor R. Brooks, Merve Kacar, Ben K. Tomlinson, Brenda W Cooper, Hong Li, Xuefei Jia, Yanwen Chen, Jenna Thomas, Paolo F. Caimi

Blood (2023) 142 (Supplement 1): 3087.

https://doi.org/10.1182/blood-2023-173943

Published: 2023

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Danai Dima, Aliya Rashid, James A Davis, Hussein Awada, Al-Ola Abdallah, Hong Li, Shaun DeJarnette, Leyla Shune, Jack Khouri, Hamza Hashmi, Joseph P McGuirk, Faiz Anwer, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2023-180368

Published: 2023

Journal Articles

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Joseph Farinella, Lauren M Granat, Hong Li, Sharon M Caroniti, Pranay S. Hegde, Matt Kalaycio, Ronald Sobecks, Claudio Brunstein, Craig S Sauter, Betty K. Hamilton

Blood (2023) 142 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2023-189629

Published: 2023

Journal Articles

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Lauren M Granat, Hong Li, Faiz Anwer, Michael Sheu, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Rajshekar Chakraborty, Chakra P Chaulagain, Willem J. van Heeckeren, Louis S. Williams

Blood (2022) 140 (Supplement 1): 4290–4291.

https://doi.org/10.1182/blood-2022-168040

Published: 2022

Journal Articles

Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Rajshekhar Chakraborty, Tapas Ranjan Behera, Hong Li, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Allison Winter, Faiz Anwer, Brad Pohlman, Ronald M. Sobecks, Betty K. Hamilton, Navneet S. Majhail

Blood (2022) 140 (Supplement 1): 10926–10927.

https://doi.org/10.1182/blood-2022-166904

Published: 2022

Journal Articles

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

Narendranath Epperla, Xinyu Wang, Hong Li, David A. Bond, Yazeed Sawalha, John C. Reneau, Timothy J. Voorhees, Kami J. Maddocks, Beth Christian, Walter Hanel, Lapo Alinari, Lalit Sehgal, Robert A. Baiocchi, James L. Lee

Blood (2022) 140 (Supplement 1): 11873–11875.

https://doi.org/10.1182/blood-2022-164907

Published: 2022

Journal Articles

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 10427–10429.

https://doi.org/10.1182/blood-2022-163464

Published: 2022

Journal Articles

A novel role for endoplasmic reticulum protein 46 (ERp46) in platelet function and arterial thrombosis in mice

Junsong Zhou, Yi Wu, Lubica Rauova, Gavin Koma, Lu Wang, Mortimer Poncz, Hong Li, Tong Liu, Karen P. Fong, Joel S. Bennett, Satya P. Kunapuli, David W. Essex

Blood (2022) 139 (13): 2050–2065.

https://doi.org/10.1182/blood.2021012055

Published: 2022

Includes: Supplemental data

Journal Articles

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

James E Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Michael H. Tomasson, Christopher A. Yasenchak, Damian J. Green, Hong Li, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah

Blood (2021) 138 (Supplement 1): 2740.

https://doi.org/10.1182/blood-2021-146047

Published: 2021

Journal Articles

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

David Taft, Clark Henderson, Christine O'Day, Changpu Yu, Hong Li, Phoenix Ho, Heather Van Epps

Blood (2021) 138 (Supplement 1): 1197.

https://doi.org/10.1182/blood-2021-150866

Published: 2021

Journal Articles

Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142299

Published: 2020

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD PhD MPH, Hong Li, Brian P. Hobbs, PhD, Aaron T. Gerds, MD MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Samjhana Bogati, RN, Eric Parsons, RN, Benjamin Pannell, Matt Kalaycio, MD, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 2595.

https://doi.org/10.1182/blood-2019-132178

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Who participates in myeloma trials? clinical and geographic predictors of access and outcomes in British Columbia, Canada.

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Factors Associated with Platelet Engraftment Following Allogeneic Hematopoietic Cell Transplantation

Effect of Prior Daratumumab Treatment on Hematopoietic Progenitor Cell Mobilization in Newly Diagnosed Multiple Myeloma

Prevalence and Outcomes of Opportunistic Infections in Steroid Refractory Graft Versus Host Disease Patients Treated with Ruxolitinib, Ibrutinib, and Belumosudil

Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia

Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Final Results of a Phase I/II Trial of Carfilzomib + R-CHOP for Frontline Treatment of Patients with Non-Germinal Center Diffuse Large B-Cell Lymphoma (DLBCL)

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study

Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Nanochip Technology for Monitoring Chemotherapy Response Using Extracellular RNAs and Proteins in Patient Plasma with Diffuse Large B-Cell Lymphoma As Biomarkers

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

A novel role for endoplasmic reticulum protein 46 (ERp46) in platelet function and arterial thrombosis in mice

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only